CD30

発現細胞

• 活性化T細胞、B細胞、NK細胞、単球

分子量

• 120 kDa

機能

• CD30L(CD153)に結合しB細胞やT細胞の増殖を増強

別名

• Ki-1

ファミリー

• TNF receptor

同

Ki, BER-H2 antigen

PrepTutorEJDIC

1. certificate of deposit / (また『C.D.』)Civil Defense民間防衛

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/08/11 22:27:23」(JST)

wiki en

[Wiki en表示]

Tumor necrosis factor receptor superfamily, member 8
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 1D01
Identifiers
Symbols	TNFRSF8 ; CD30; D1S166E; Ki-1
External IDs	OMIM: 153243 MGI: 99908 HomoloGene: 949 GeneCards: TNFRSF8 Gene
Gene ontology Molecular function • transmembrane signaling receptor activity Cellular component • cytoplasm • plasma membrane • integral component of membrane • extracellular exosome Biological process • signal transduction • negative regulation of cell proliferation • positive regulation of tumor necrosis factor biosynthetic process • positive regulation of apoptotic process • positive regulation of TRAIL biosynthetic process • cellular response to mechanical stimulus Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	943	21941
Ensembl	ENSG00000120949	ENSMUSG00000028602
UniProt	P28908	Q60846
RefSeq (mRNA)	NM_001243	NM_009401
RefSeq (protein)	NP_001234	NP_033427
Location (UCSC)	Chr 1: 12.06 – 12.14 Mb	Chr 4: 145.27 – 145.32 Mb
PubMed search	[1]	[2]

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.

Cancer treatment

CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:

1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen

Interactions

CD30 has been shown to interact with TRAF5, TRAF1, TRAF2 and TRAF3.

References

Further reading

• Schneider C, Hübinger G (Jul 2002). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family". Leukemia & Lymphoma 43 (7): 1355–66. doi:10.1080/10428190290033288. PMID 12389614. 
• Horie R, Higashihara M, Watanabe T (Jan 2003). "Hodgkin's lymphoma and CD30 signal transduction". International Journal of Hematology 77 (1): 37–47. doi:10.1007/BF02982601. PMID 12568298. 
• Tarkowski M (Jul 2003). "Expression and a role of CD30 in regulation of T-cell activity". Current Opinion in Hematology 10 (4): 267–71. doi:10.1097/00062752-200307000-00003. PMID 12799531. 
• Granados S, Hwang ST (Jun 2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases". The Journal of Investigative Dermatology 122 (6): 1345–7. doi:10.1111/j.0022-202X.2004.22616.x. PMID 15175022. 
• Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (Feb 1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell 68 (3): 421–7. doi:10.1016/0092-8674(92)90180-K. PMID 1310894. 
• Fonatsch C, Latza U, Dürkop H, Rieder H, Stein H (Nov 1992). "Assignment of the human CD30 (Ki-1) gene to 1p36". Genomics 14 (3): 825–6. doi:10.1016/S0888-7543(05)80203-4. PMID 1330892. 
• Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay". European Journal of Immunology 19 (1): 157–62. doi:10.1002/eji.1830190125. PMID 2537734. 
• Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl V (Oct 1982). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". International Journal of Cancer. Journal International Du Cancer 30 (4): 445–59. doi:10.1002/ijc.2910300411. PMID 6754630. 
• Jung W, Krueger S, Renner C, Gause A, Sahin U, Trümper L, Pfreundschuh M (Dec 1994). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology 31 (17): 1329–34. doi:10.1016/0161-5890(94)90051-5. PMID 7527901. 
• Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S (Jun 1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3". Oncogene 9 (6): 1567–74. PMID 8183550. 
• Lee SY, Park CG, Choi Y (Feb 1996). "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors". The Journal of Experimental Medicine 183 (2): 669–74. doi:10.1084/jem.183.2.669. PMC 2192463. PMID 8627180. 
• Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB (May 1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". The Journal of Biological Chemistry 271 (22): 12852–8. doi:10.1074/jbc.271.22.12852. PMID 8662842. 
• Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T (Oct 1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages". Blood 88 (7): 2422–32. PMID 8839832. 
• Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry 272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID 8999898. 
• Lee SY, Lee SY, Choi Y (Apr 1997). "TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation". The Journal of Experimental Medicine 185 (7): 1275–85. doi:10.1084/jem.185.7.1275. PMC 2196258. PMID 9104814. 
• Boucher LM, Marengère LE, Lu Y, Thukral S, Mak TW (Apr 1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily". Biochemical and Biophysical Research Communications 233 (3): 592–600. doi:10.1006/bbrc.1997.6509. PMID 9168896. 
• Duckett CS, Thompson CB (Nov 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development 11 (21): 2810–21. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251. 
• Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J (Jan 1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)". Gene 207 (2): 135–40. doi:10.1016/S0378-1119(97)00616-1. PMID 9511754. 
• Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR (Mar 1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells". Nature 398 (6725): 341–4. doi:10.1038/18692. PMID 10192335. 

External links

• CD30 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. ALK陽性未分化大細胞型リンパ腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of anaplastic large cell lymphoma alk positive
• 2. リンパ腫様丘疹症 lymphomatoid papulosis
• 3. 菌状息肉腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of mycosis fungoides
• 4. 末梢性T細胞性リンパ腫分類不能型の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of peripheral t cell lymphoma not otherwise specified
• 5. 古典型ホジキンリンパ腫の疫学、病理学的特徴、および診断 epidemiology pathologic features and diagnosis of classical hodgkin lymphoma

English Journal

• Recurrent ALK-Negative Anaplastic Large T-Cell Lymphoma Presenting as Necrotizing Vasculitis.

• Nambudiri VE, Aboutalebi A, Granter SR, Saavedra A.Source*Department of Dermatology, Harvard Medical School, Boston, MA Departments of †Pathology ‡Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
• The American Journal of dermatopathology.Am J Dermatopathol.2013 Jun;35(4):512-6. doi: 10.1097/DAD.0b013e31827a0cda.
• : Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma histologically characterized by expression of CD30, a cell surface receptor present on activated T cells and B cells. ALCL may occur in a primary cutaneous form or as systemic ALCL with lymph node involvement. Anaplastic lymphoma kinase (A
• PMID 23291583

• Peripheral T-cell Lymphomas of Follicular T-Helper Cell Derivation With Hodgkin/Reed-Sternberg Cells of B-cell Lineage: Both EBV-positive and EBV-negative Variants Exist.

• Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M, Jaffe ES.Source*Hematopathology Section §Molecular Diagnostics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD †Department of Pathology, Loyola University Medical Center, Maywood, IL ‡Centro de Patología CEPACIT, Buenos Aires, Argentina.
• The American journal of surgical pathology.Am J Surg Pathol.2013 Jun;37(6):816-26. doi: 10.1097/PAS.0b013e3182785610.
• Peripheral T-cell lymphomas (PTCLs) are functionally and morphologically complex. Epstein-Barr virus (EBV)-positive B cells have been reported in angioimmunoblastic T-cell lymphoma (AITL) and other PTCLs and may mimic Hodgkin/Reed-Sternberg (HRS) cells, but EBV-negative HRS-like B cells have not bee
• PMID 23598959

Japanese Journal

• 皮膚のリンパ腫とケモカイン

• 菅谷 誠
• 日本臨床免疫学会会誌 34(2), 91-98, 2011
• … しており，病勢マーカーとして有用である．またCXCL9，CXCL10は表皮向性，CCL21はリンパ節への浸潤，CXCL12は腫瘍細胞のCD26発現低下と関係していることが知られている．さらにCXCL13は皮膚へのB細胞の浸潤，CCR3はCD30陽性リンパ増殖症との関与が考えられている．CCR4を治療のターゲットとした抗体療法が，CCR4陽性T細胞リンパ腫とアレルギー性疾患に対して開発されつつあり，今後もケモカインと受容体に関する研究よって …
• NAID 130000850593

• CD30-positive anaplastic variant diffuse large B cell lymphoma : a rare case presented with cutaneous involvement

• ASANO Hiroki,IMAI Yoichi,OTA Satoshi,YAMAMOTO Go,TAKAHASHI Tsuyoshi,FUKAYAMA Masashi,KUROKAWA Mineo
• International journal of hematology 92(3), 550-552, 2010-10-15
• NAID 10027673757

Related Links

• (ﾓﾉｸﾛｰﾅﾙ抗体による)ﾘﾝﾊﾟ球表面ﾏｰｶｰの自動解析CD30 - SRL.INFO

CD30抗原(Ki-1)は,分子量105kDaの単鎖糖タンパクです。一般的に活性化T,B細胞 およびRS細胞等の悪性リンパ腫の一部に発現します。臨床的には,ATL,ホジキン病,Ki- 1リンパ腫に有用なマーカーで,白血病・リンパ腫を含む細胞の型分類等に用いられてい ...

Related Pictures

---

★リンクテーブル★

国試過去問	「113C047」
リンク元	「悪性リンパ腫」「表面抗原分類」「サイトカイン受容体」
関連記事	「CD3」「CD」

「113C047」

　　[★]

• 24歳の女性。発熱と頸部腫瘤を主訴に来院した。2か月前から左頸部腫瘤を自覚していた。2週間前に発熱と寝汗が出現し、改善しないため受診した。6か月で7kgの体重減少があった。体温 37.8℃。脈拍 96/分、整。左頸部、左鎖骨上窩および両側鼠径部に弾性硬、圧痛のない径2～3cmのリンパ節を4個触知する。左頸部リンパ節の生検組織のH-E染色標本(別冊No. 6)を別に示す。免疫染色ではCD30陽性の細胞を認める。
• この患者に行う治療に含むべき薬剤はどれか。

• a　イソニアジド
• b　リツキシマブ
• c　ビンクリスチン
• d　ブレオマイシン
• e　全トランス型レチノイン酸

[正答]

D

※国試ナビ4※　［113C046］←［国試_113］→［113C048］

「悪性リンパ腫」

　　[★]

英

malignant lymphoma

ラ

lymphoma malignum

関

悪性リンパ腫とマーカー

悪性リンパ腫.xls

sIg

CD5

CD10

CD19

CD20

CD23

CD43

bcl

cyclin

TdT

その他

転座

小リンパ性リンパ腫 small lymphocytic lymphoma 慢性リンパ性白血病 chronic lymphocytic leukemia

＋

＋

＋

＋

＋

－

－

－

濾胞性リンパ腫 FL

＋

－

＋

＋

bcl2　＋

－

MALTリンパ腫

－

－

＋

マントル細胞リンパ腫 MCL

＋

＋

－

＋

＋

びまん性大細胞性B細胞リンパ腫 DLBL

＋

－

＋／－

＋

＋

bcl6　＋

前駆Bリンパ芽球性リンパ腫 急性Bリンパ球性白血病 LBL/ALL

－

＋

＋

バーキットリンパ腫 BL

＋

－

＋

＋

＋

Myc, Ki-67

ｔ（8,14)Myc；IgH　～80% t(2,8)κ；Myc　～15%

ホジキンリンパ腫

CD15, CD30, CD45 -

t(8,22)Myc；λ　～10%

成人T細胞白血病 ATL

CD2, CD3, CD4, CD25, HLA-DR, CD8 -

病期

• Ann Arbor分類

参考

• 1.

http://www.rinpashu.com/inspection/

国試

• 100D031

「表面抗原分類」

　　[★]

英

cluster of differentiation, CD

• 細胞の表面抗原を認識する抗体を整理した分類

Bリンパ球 CD10,CD19,CD20

Tリンパ球 CD2,CD3,CD5,CD7

幹細胞 CD34

顆粒球 CD13,CD33

単球 CD14：LPSをリガンドとし、Toll-like receptorと共役して細胞内シグナルを伝達する分子。

巨核球 CD41(GpIIb),CD42(GpIb)

NK細胞：CD16(IgGのFc部に対する受容体)、CD56(NCAM-I)

CD1	CD21	CD41	CD61	CD81
CD2	CD22	CD42	CD62	CD82
CD3	CD23	CD43	CD63	CD83
CD4	CD24	CD44	CD64	CD84
CD5	CD25	CD45	CD65	CD85
CD6	CD26	CD46	CD66	CD86
CD7	CD27	CD47	CD67	CD87
CD8	CD28	CD48	CD68	CD88
CD9	CD29	CD49	CD69	CD89
CD10	CD30	CD50	CD70	CD90
CD11	CD31	CD51	CD71	CD91
CD12	CD32	CD52	CD72	CD92
CD13	CD33	CD53	CD73	CD93
CD14	CD34	CD54	CD74	CD94
CD15	CD35	CD55	CD75	CD95
CD16	CD36	CD56	CD76	CD96
CD17	CD37	CD57	CD77	CD97
CD18	CD38	CD58	CD78	CD98
CD19	CD39	CD59	CD79	CD99
CD20	CD40	CD60	CD80	CD100

「サイトカイン受容体」

　　[★]

英

cytokine receptor

関

サイトカイン

• 多ユニット構造を取ることが特徴である。

サイトカイン受容体ファミリー

• 細胞外領域に200a.a.からなる共通構造を有する。

• HRF motif, hematopoietin receptor family motif

• 細胞外領域のN末側に4つのCysが存在
• 細胞外領域の膜貫通部位付近にWSXWSモチーフが存在

shared γc	IL-2, IL-4, IL-7, IL-9, IL-13, IL-15
shared gp130	IL-6, G-CSF, IL-11, IL-12, LIF, OSM, CNTF
shared gp140	IL-3, IL-5, GM-CSF

チロシンキナーゼファミリー

• TKF motif(tyrosine kinase family motif)
• EGF, PDGF, FGF, SCF

IL-1受容体ファミリー

• TLRと共通領域がある
• IL-1

TNF受容体ファミリー

• death domainを持つ
• TNF, Fas, CD40, CD30

ケモカイン受容体ファミリー

• ７回膜貫通型
• ケモカイン受容体
• IL-8, MCP

「CD3」

　　[★]

関

TCR, ζ

• T細胞のマーカーとして使われる。

発現細胞

• 胸腺細胞、T細胞

機能

• Associated with the T-cell antigen receptor(TCR)

• ζと共にTCRで受容したシグナルを細胞内に伝達する

「CD」

　　[★]

• 表面抗原分類 cluster of differentiation
• 膠原病 collagen disease
• 集合管 collecting duct
• クローン病 Crohn's disease